Literature DB >> 34907481

Selectivity mechanism of phosphodiesterase isoform inhibitor through in silico investigations.

Junhao Huang1,2,3, Baichun Hu1,2,4, Ziqi Xu3, Yunxia Ye3, Huibin Wang3, Shuxiang Wang3, Zhilong Liu3, Jian Wang5,6,7.   

Abstract

Understanding the selectivity mechanism of inhibitors towards homology proteins helps to design selective candidates. Phosphodiesterase (PDE) family members act in the degradation of cAMP and cGMP, among which some isoforms such as PDE9A are attracting interest for Alzheimer's disease treatment, while PDE10A is used as target for treating schizophrenia. In this study, computational methods were used to investigate the major features of PDE9A/10A, with the purpose to provide deep understanding of the molecular mechanism of selective inhibition towards these two isoforms. Our result revealed that two conserved residues Gln453 and Phe456 were proven to be crucial for the binding affinity and inhibitory selectivity of PDE9A inhibitors. In addition, the high-affinity PDE9A inhibitors always interact with the conservative hydrophobic pocket as well as Tyr424 and Ala452 of PDE9A, while PDE10A selective inhibitors need to have two hydrophobic groups and two hydrogen bond donors to interact with the conservative Tyr693, Gln726, and Phe729 of PDE10A. This study provides valuable insights into the underlying mechanism of selective inhibition targeting PDE9A and PDE10A, for further search for potent and highly selective PDE9A/10A inhibitors.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Molecular dynamics simulation; Phosphodiesterase; QM/MM calculation; Selective inhibitor

Mesh:

Substances:

Year:  2021        PMID: 34907481     DOI: 10.1007/s00894-021-04934-7

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  25 in total

Review 1.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.

Authors:  S Miyamoto; G E Duncan; C E Marx; J A Lieberman
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

Review 2.  Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity.

Authors:  Hengming Ke; Huanchen Wang
Journal:  Curr Top Med Chem       Date:  2007       Impact factor: 3.295

Review 3.  Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling.

Authors:  Marco Conti; Joseph Beavo
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

Review 4.  Spatiotemporal control of cAMP signalling processes by anchored signalling complexes.

Authors:  E Jarnaess; K Taskén
Journal:  Biochem Soc Trans       Date:  2007-11       Impact factor: 5.407

Review 5.  Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Authors:  Andrew T Bender; Joseph A Beavo
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 6.  Overview of PDEs and their regulation.

Authors:  Kenji Omori; Jun Kotera
Journal:  Circ Res       Date:  2007-02-16       Impact factor: 17.367

Review 7.  Molecular diversity of cyclic AMP signalling.

Authors:  F A Antoni
Journal:  Front Neuroendocrinol       Date:  2000-04       Impact factor: 8.606

Review 8.  Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease.

Authors:  Fernanda G De Felice; Ana Paula Wasilewska-Sampaio; Anna Carolina A P Barbosa; Flavia C A Gomes; William L Klein; Sérgio T Ferreira
Journal:  Curr Alzheimer Res       Date:  2007-07       Impact factor: 3.498

9.  The role of cyclic nucleotides in axon guidance.

Authors:  Michael Piper; Francis van Horck; Christine Holt
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

Review 10.  cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology.

Authors:  Manuela Zaccolo; Matthew A Movsesian
Journal:  Circ Res       Date:  2007-06-08       Impact factor: 17.367

View more
  1 in total

1.  Functional characteristics and research trends of PDE11A in human diseases (Review).

Authors:  Gyeyeong Kong; Hyunji Lee; Thuy-Trang T Vo; Uijin Juang; So Hee Kwon; Jisoo Park; Jongsun Park; Seon-Hwan Kim
Journal:  Mol Med Rep       Date:  2022-08-05       Impact factor: 3.423

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.